Expert guides on supplement manufacturing, FDA compliance, cost optimization, and scaling your CPG business.
A 9-section mock recall simulation checklist covering scenario definition, raw material and production traceability, finished goods disposition, customer shipment mapping, response time documentation, gap analysis, and QA sign-off archiving. Designed for supplement, cosmetics, food, and CPG manufacturers running FSMA 204-aligned recall drills.
A 15-point inspection checklist for every raw material delivery, covering identity and integrity verification, COA potency deep-dives, FSMA 204 traceability logging, potency-based scaling triggers, and QA signature release. Includes the Potency Variance Loss framework and cross-references to the FSMA 204 Traceability Checklist.
A complete audit checklist and SOP for FSMA 204 compliance, covering the Digital Spine technical requirements, all three Critical Tracking Events (Receiving, Transformation, Shipping), a timed Stress Test for mock audits, and a ready-to-use Standard Operating Procedure for responding to an FDA 24-hour data request.
A complete manual for quality managers, covering how the Copilot applies 21 CFR Part 111, FSMA 204, and ISO 22716, a full ALCOA+ compliance map, a 20-prompt library, a 5-step pre-audit workflow, and an SOP template you can hand to an auditor.
A product recall is the moment your documentation infrastructure either protects your business or exposes it. This checklist walks you through the first 72 hours, the records you need to pull, stakeholder notifications, and the self-test that determines whether you can target one lot, or must pull your entire inventory.
Receiving an FDA Warning Letter triggers a public record, retailer alerts, and a strict response timeline. This guide walks you through the immediate 48-hour response, what documentation to pull, exactly what your formal response must contain, and a full pre-inspection documentation checklist to build now.
Data-backed insights from the front lines of formulation, compliance, and scale. `[NEEDS OWNER REVIEW: confirm sample size/methodology before final publish]` The report's benchmark data puts average raw material lead times at 81 days, outlines 3 commonly-missed MoCRA audit failure points, and finds AI-assisted labs cutting R&D cycles by up to 30% among surveyed facilities. Includes the Batch Health Index (BHI) framework for benchmarking your facility.
A Certificate of Analysis is the most-requested document in the hemp supply chain, but what retailers actually check goes well beyond a basic cannabinoid panel. Use this checklist before submitting to any retail buyer, marketplace, or certification program.
GLP-1 adjacent supplements are one of the most scrutinized categories in the current FDA enforcement environment. Audit your documentation practices against the standard an inspector or retail buyer would expect, before they do.
A practical breakdown of the 4 critical failure points that trigger FDA enforcement actions in 2026, from safety substantiation gaps to the 15-day adverse event clock. Includes a full MoCRA & GMP Readiness Checklist to benchmark your facility against current enforcement standards.
`[NEEDS OWNER REVIEW: confirm methodology/sourcing before final publish]` A deep dive into the financial architecture of Potency Variance Loss (PVL) and Batch Consistency ROI. Learn how a widely-cited ~88% spreadsheet error rate (a general spreadsheet-accuracy statistic, not a CPG-specific figure) illustrates how small errors compound into six-figure losses, and see the math behind potency-based scaling that can recover $500K–$1M in annual ingredient spend for manufacturers with comparable volume.
A practical self-assessment checklist that transforms complex 2026 FDA regulations into actionable Yes/No benchmarks. Score your facility across 5 phases, from facility registration and safety dossiers to post-market vigilance and ALCOA+ data integrity, and find out if you're Audit-Ready or Audit-Risky.
Monthly enforcement pattern analysis, pulled directly from FDA's public Warning Letter database as new letters post
A 25-letter telehealth sweep over compounded GLP-1 marketing, a sterility and data integrity failure at Wizcure Pharmaa, an "indication creep" device warning to BlephEx, and a wave of unauthorized-device citations. Four different mechanisms, one pattern: claims and processes drifting past what was actually validated -- and what locked MMRs, e-signature gates, and cryptographic audit trails do to stop it.
Two manufacturers. Two facilities. One in the U.S., one in Canada. Both received Warning Letters on the same day for the same two violations: failing to independently test incoming components and a quality unit that approved deficient specs without scrutiny. Here's what happened and what it means for your operation.
Being a contract manufacturer doesn't transfer your compliance obligations to the brand owner. This issue covers Asanuma Corporation's June 2026 Warning Letter -- the same component testing and quality unit failures as Issue 1, plus two things the others didn't have: a clear FDA position on contractor liability and an import alert that arrived before the Warning Letter was even issued.
Every issue covers real Warning Letters posted to the FDA public database — what the violations were, why they matter, and what to look for in your own operation.
All issues →Try BatchBuddy free for 14 days. No hidden fees, cancel anytime.
Start Free TrialA subpart-by-subpart walkthrough of 21 CFR Part 111 CGMP requirements for dietary supplements: personnel, production controls, master and batch records, identity testing, and how Part 11 intersects once records go electronic.
Everything cosmetics manufacturers need to know about the Modernization of Cosmetics Regulation Act: facility registration, product listing, Responsible Person duties, the 15-day adverse event clock, and the coming GMP rule.
Most compliance gaps aren't the result of carelessness. They're the result of software that was never designed to handle them automatically. Here are the 10 things that come up most often in FDA inspections, and what it looks like when the system just handles them for you.
FDA 483 observations aren't a fine - but they start a clock. Learn what they mean, how to respond within 15 days, and how BatchBuddy prevents repeat findings.
Most EBR software is digital paper: forms with a submit button. This guide explains what structurally enforced EBR looks like, the specific questions that separate compliant systems from ones that fail FDA inspections, and why the enforcement has to live in the architecture, not the SOP.
The FDA is investing in AI-assisted, records-first oversight, including ELSA, its internal generative-AI assistant. Most operations still running on spreadsheets won’t survive the knock on the door. Here’s what GMP Native™ documentation looks like, and how to make sure you’re ready before the investigator arrives.
Enterprise-grade cryptographic integrity, public validation packs, and honest compliance documentation should never have been a luxury. Here's why we built HMAC v3 signing, published our validation evidence openly, and priced the Manufacturer plan at $749/month.
Most manufacturers have lot traceability. Very few have ever actually tested it. Learn what recall simulation is, why traceability alone does not equal recall readiness, and how Batch Buddy automates the entire process in minutes using your real production data. Free checklist included.
Amazon now requires all dietary supplement brands to prove cGMP certification from an accredited third-party auditor. Here's what contract manufacturers need to document, why the compliance pressure lands on you, and how to be ready before a 90-day notice arrives.
How Batch Buddy's AI Copilot applies 21 CFR Part 11, FSMA 204, ISO 22716, SQF, and BRC frameworks to your records, including an ALCOA+ compliance map, a 20-prompt library, a step-by-step pre-audit workflow, and an SOP template.
A Warning Letter is public, permanent, and sets off a chain of events most manufacturers are not prepared for. Here is exactly what happens, what your response needs to contain, and why documentation is almost always at the center of it.
Amazon, Whole Foods, NSF certification, and natural channel retailers all require COAs for hemp products, but what they actually check goes well beyond a basic cannabinoid panel. Here is the full documentation standard.
The FDA has not finalized its hemp regulatory framework, but the documentation direction is clear. Here is the GMP batch record standard hemp manufacturers need to build now, before it is required.
Delta-8 THC is legal under the Farm Bill, banned in a dozen states, and disputed at the federal level, all at once. Here is the documentation manufacturers in the converted cannabinoid space need to protect themselves.
Major retailers, NSF certification, and Amazon quality programs are quietly raising the documentation bar for collagen peptide manufacturers. Here is exactly what they are looking for and how to get there.
BPC-157, TB-500, and research peptides are one of the hottest supplement categories, and one of the most scrutinized. Here is what manufacturers need documented before the next enforcement wave hits.
Berberine and natural GLP-1 supplements are the hottest category in the industry. Here is why rapid scaling without solid batch documentation is a regulatory risk, and how manufacturers stay protected.
System integration, data integrity, employee resistance, and implementation cost are the four challenges manufacturers face with EBR software. Here is an honest look at each one and how modern platforms have solved them.
Learn what FSMA 204 actually requires, why one-up one-back traceability is no longer enough, and how food manufacturers can meet the 24-hour FDA records deadline and retailer demands without a dedicated compliance team.
Learn the complete workflow from formulation to FDA-compliant supplement label, including Supplement Facts panel requirements, allergen declarations, common labeling mistakes, and how integrated platforms like Batch Buddy and Label Buddy eliminate errors.
Learn the critical differences between a change log and a true 21 CFR Part 11 audit trail. Includes five practical tests to evaluate your current system and common FDA inspection findings.
Learn which electronic signature methods actually meet FDA 21 CFR Part 11 requirements. Covers compliant vs. non-compliant approaches, common inspection findings, and how to build a defensible signature workflow.
Compare the traditional consultant-heavy compliance model with software-led compliance. Learn how automated audit trails, electronic signatures, and electronic batch records reduce cost and improve FDA inspection readiness.
Navigate the new MoCRA enforcement and FDA 21 CFR Part 11 requirements. Learn what facility registration, adverse event reporting, and digital compliance mean for your manufacturing operation.
A complete guide to FDA 21 CFR Part 11 electronic records and signature requirements: scope, closed vs. open systems, audit trails, electronic signatures, and validation.
Learn how supplement batch record software replaces paper-based systems to improve accuracy, traceability, and FDA audit readiness, plus what to look for when evaluating batch record solutions.
Try BatchBuddy free for 14 days. No hidden fees, cancel anytime.
Start Free Trial